Currently, aspirin plus clopidogrel is considered as a standard acute treatment of ischemic stroke, based on results of CHANCE and POINT trial. However, still a considerable portion of patients showed early stroke recurrence, especially in those with stroke due to large artery atherosclerosis. Cilostazol may have benefit in reducing early stroke recurrence of neurologic deterioriation. The post-hoc analysis of CSPS.com showed that use of cilostazol after 15 days of stroke was effective for preventing subsequent stroke. The effect of adding cilostazol was more effective in those with large artery atherosclerosis and those receiving clopidogrel than aspirin.

Start Date15 Mar 2025

Sponsor / Collaborator

Asan Medical Center

[+1]

ISRCTN44436843

/ RecruitingPhase 3IIT

The LACunar Intervention Trial 3 (LACI-3). Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke.

Start Date03 Mar 2025

Sponsor / Collaborator

The University of Edinburgh

[+1]

NCT06715007

/ Not yet recruitingNot ApplicableIIT

Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases

Cerebral small vessel disease (cSVD) is a common accompaniment of aging. Recent small subcortical (or lacunar) infarcts (i.e. symptomatic cSVD) and white matter hyperintensities are typical cSVD lesions on neuroimaging. cSVD causes about a quarter of ischaemic strokes and related with cognitive dysfunction. However, few studies are available so far to especially explore the treatment of cSVD. Endothelial dysfunction plays an important part in cSVD. Cilostazol and isosorbide mononitrate have endothelial protective function. We designed this prospective cohort study in China, aiming to evaluate the effect of different antiplatelet agents (e.g. Cilostazol) on cSVD and retina in patients with cSVD (recent small subcortical infarcts or WMH, respectively).

Start Date20 Dec 2024

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

100 Clinical Results associated with Cilostazol

100 Translational Medicine associated with Cilostazol

100 Patents (Medical) associated with Cilostazol

3,236

Literatures (Medical) associated with Cilostazol

01 Apr 2025·ESC Heart Failure

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

Article

Author: Martin, Cindy M. ; Nijjar, Prabhjot S. ; Aiad, Norman ; Meyer, Markus ; Lahiri, Julie A. ; Alexy, Tamas ; du Fay de Lavallaz, Jeanne ; Zhang, Michael J. ; Chaikijurajai, Thanat ; Ye, Bo

AbstractBackground and AimsPatients with heart failure with preserved ejection fraction (HFpEF) tend to have low resting and exercise heart rates. Phosphodiesterase‐3 (PDE‐3) inhibitors improve heart rates, haemodynamics and symptoms in patients with HFpEF. Cilostazol is an oral PDE‐3 inhibitor used in peripheral artery disease. This study thought to evaluate the short‐term effects of cilostazol on health status, N‐terminal brain natriuretic peptide (NT‐proBNP) levels and mechanisms of action.MethodsThe effect of cilostazol was evaluated in 23 patients with HFpEF in a randomized placebo controlled multiple crossover trial (CLIP‐HFpEF). Participants received placebo or cilostazol for 1 week followed by three crossovers to the alternate assignment at weeks 2, 3 and 4. The primary endpoint was the Kansas City Cardiomyopathy Questionnaire (KCCQ‐12) overall summary score obtained at the end of each treatment period. NT‐proBNP was the secondary endpoint. In an exploratory mechanistic analysis, pulmonary artery (PA) pressures and heart rates were followed amongst the five participants with implanted pressure monitors.ResultsCilostazol improved the KCCQ score by 4.8 points (95% confidence interval, 2.0–7.7, P = 0.003). NT‐proBNP levels were 448 (154–1056) pg/mL on placebo and 375 (68–974) pg/mL on cilostazol (P = 0.006). In patients with PA pressure monitors, diastolic pressure was 20.5 (18.7–23.0) mmHg on placebo and 18.0 (17.0–20.0) mmHg on cilostazol, an effect linked to higher heart rates (P < 0.001).ConclusionsAmongst patients with HFpEF, short‐term treatment with cilostazol leads to improvements in health status and NT‐proBNP when compared with placebo. These effects are likely conveyed by a heart rate‐dependent reduction in cardiac filling pressures.Trial RegistrationClinicalTrials.gov Identifier: NCT05126836.

01 Mar 2025·Internal Medicine Journal

Efficacy and safety of using cilostazol versus aspirin in secondary stroke prevention: systematic review and meta‐analysis of randomised controlled clinical trials

Article

Author: Zheng, Zhenyong ; Huang, Yi‐min ; Zhang, Xiaodie ; Zhuang, Ping

AbstractBackgroundSecondary stroke prevention is crucial for reducing recurrent events and associated morbidity. Cilostazol, a phosphodiesterase III inhibitor, is considered an alternative to aspirin for patients with ischaemic stroke due to its potentially lower risk of haemorrhagic complications. This meta‐analysis evaluates the efficacy and safety of cilostazol versus aspirin for secondary stroke prevention. It provides a basis for drug selection and observation of secondary stroke prevention strategies.MethodsA comprehensive search was conducted in PubMed, Cochrane Library, EMBASE and Web of Science databases for randomised controlled trials comparing cilostazol with aspirin in secondary stroke prevention. Key outcomes included recurrence of ischaemic stroke, intracranial haemorrhage (ICH), death, effective rate and incidence of adverse events. Meta‐analysis was performed using a random‐effects model, and heterogeneity was assessed using I2 statistics and Cochran's Q test. Publication bias was evaluated using Doi plots and Luis Furuya‐Kanamori index.ResultsThirteen studies involving 8993 participants were included. Cilostazol significantly reduced the recurrence of ischaemic stroke (risk ratio (RR): 0.766, 95% confidence interval (CI): 0.624–0.941) and ICH (RR: 0.392, 95% CI: 0.250–0.616) compared to aspirin. No significant differences were observed in overall mortality or adverse events. Cilostazol increased risks of headache, dizziness, diarrhoea and tachycardia but reduced constipation. Heterogeneity was generally low to moderate.ConclusionCilostazol is an effective alternative to aspirin for secondary stroke prevention, reducing the risk of recurrent ischaemic stroke and ICH. However, its use is associated with certain adverse effects. Clinicians should consider individual patient profiles and preferences when selecting anti‐platelet therapy for stroke prevention. Further research is warranted to optimise cilostazol use in clinical practice.

01 Mar 2025·Journal of Vascular Surgery

Cilostazol after endovascular therapy for femoropopliteal peripheral arterial disease: A systematic review and meta-analysis

Review

Author: Vargas, Ana ; Alia, Valentine S. ; Garza, Alejandro ; Cerecedo, Christian D. ; Candil, Alejandro J. ; Candil, Alejandro J ; Alia, Valentine S ; Cerecedo, Christian D ; Silva, Aaron ; El Shazly, Omar

BACKGROUNDEndovascular therapy (ET) outcomes for femoropopliteal peripheral arterial disease (FP-PAD) remain suboptimal. Cilostazol therapy may improve patency rates and decrease major adverse limb events after ET for FP-PAD. Our goal was to analyze published studies evaluating the use of cilostazol after ET for FP-PAD.METHODSWe searched MEDLINE, EMBASE, and CENTRAL for randomized and observational studies (OSs) evaluating cilostazol therapy after ET for FP-PAD. We only included OSs adjusting for confounding variables. We analyzed observational and randomized studies separately and explored heterogeneity by estimating an I² statistic. A fixed-effects model was chosen if the I² statistic was low. If the two-sided probability of observing the difference between groups under a true null hypothesis was <5%, we considered this difference statistically significant.RESULTSWe screened 2171 studies and included 26 papers in our analysis (5 randomized controlled trials and 21 OSs). All randomized studies were open label. In randomized studies, the odds of restenosis were lower in patients treated with cilostazol (pooled odds ratio, 0.28; 95% confidence interval [CI], 0.18-0.43; P < .01; I² = 0%). The odds of target lesion revascularization (TLR) were also lower in patients treated with cilostazol (pooled odds ratio, 0.35; 95% CI, 0.22-0.65; P < .01; I² = 0%). In OSs, we also identified associations between peri-interventional treatment with cilostazol and lower rates of restenosis (pooled hazard ratio [pHR], 0.57; 95% CI, 0.51-0.65; P < .01; I² = 34%), TLR (pHR, 0.53; 95% CI, 0.36-0.79; P < .01; I² = 0%), and amputation (pHR, 0.54; 95% CI, 0.32-0.90; P = .02; I² = 30%).CONCLUSIONSIn randomized open-label studies, peri-interventional treatment with cilostazol after ET for FP-PAD decreased the odds of restenosis and TLR (Level 1A). Similarly, in OSs that adjusted for confounding, peri-interventional cilostazol therapy was associated with lower rates of restenosis, TLR, and amputation (Level 2A).

News (Medical) associated with Cilostazol

28 May 2024

·www.prnewswire.com

Genovate Announces Plans to Submit a New Drug Application for PMR to the U.S. Food & Drug Administration in the Second Half of 2025

TAIPEI, May 28, 2024 /PRNewswire/ -- Genovate Biotechnology Co., Ltd. (TPEx: 4130), a Taiwan-based specialty pharmaceutical company, today announced its plans to submit a New Drug Application (NDA) with the United States Food and Drug Administration (US FDA) for PMR, an investigational once daily extended-release form of cilostazol for the treatment of Intermittent Claudication, in the second half of 2025. In the written responses to the pre-NDA meeting package, the FDA confirmed that the clinical studies conducted are sufficient to support the submission of a marketing application under the 505(b)(2) regulatory pathway. The key study in the submission package, GBL23-001 (NCT06167265), is a randomized, fully replicate crossover study designed to evaluate the bioequivalence and within-subject variability between PMR 145 mg once daily and the immediate-release tablet of cilostazol 100 mg twice daily. This study is expected to be completed in mid-2024, and the top-line results have shown that the primary endpoints of the study were achieved, and the decision to submit the application was made following the successful outcome of study GBL23-001. Furthermore, Genovate has been improving the PMR formulation and its manufacturing processes in order to address additional FDA comments. All clinical study and manufacturing data are expected to be included in the final submission package. "We are pleased to share what we believe is an efficient regulatory pathway for PMR with the goal of bringing a new treatment option to the people who suffer from intermittent claudication and recurrence of cerebral infarction, from the US to the globe." said Chia-Chen Chu, General Manager of Genovate. About PMR (Cilostazol Extended-Release Tablets) PMR, a novel extended-release (ER) formulation of cilostazol, was designed to reduce the concentration-dependent side effects associated with immediate-release (IR) tablet form of cilostazol. Cilostazol is currently available in IR tablet form at 50 and 100 mg strengths administered twice daily. The IR formulation of cilostazol, marketed as Pletal® in the US (Pletaal® in Taiwan and other Asian countries), was first available in Japan in 1988 for the treatment of peripheral arterial diseases and the prevention of recurrence of cerebral infarction and later approved by the US FDA in 1999 for the treatment of intermittent claudication (IC). Cilostazol is a specific PDE III inhibitor that can cause reduced platelet aggregation and increased vasodilatation. Cilostazol showed good efficacy in preventing secondary strokes, notably reducing the rates of ischaemic stroke recurrence. Nevertheless, the results from eight placebo-controlled clinical trials indicated that 15.4% of patients withdrawn from cilostazol treatment were as a result of adverse reactions. Headache, palpitations, and diarrhea were the most frequently reported adverse reactions among these patients. These adverse reactions were attributable to the peak concentration of cilostazol. Genovate is developing an ER tablet form of cilostazol, PMR, to be administered once daily aiming to improve adherence and to reduce the side effects associated with the high peak-to-trough variation of the concentration of cilostazol IR. About Intermittent Claudication Peripheral arterial disease (PAD) affects over 200 million people globally and around 8.5 million Americans over the age of 40. PAD occurs as a result of the narrowing or blockade of blood vessels that carry blood from the heart to the legs. The main symptom of PAD observed in approximately 70% of patients is intermittent claudication (IC), a condition that presents as pain and cramping in the lower extremities (thigh, calf, hip and buttock muscles), as a result of limited blood flow. IC is commonly viewed as a signal of substantial atherosclerosis, suggesting a higher likelihood of heart attack or stroke. The symptoms of IC are intermittent, exacerbated when walking or during exercise, and are alleviated with rest, but reoccur when activity resume; as a result, IC can be very debilitating, drastically affecting the quality of life of those affected. In severe cases, IC may require surgical intervention, but in general, it can be treated and managed with a combinational approach including medication, life style changes that modify or eliminate risk factors, and exercise program. Drugs improving blood flow such as anti-clotting agents (aspirin), anti-hypertensives, statins, and phosphodiesterase (PDE) III inhibitors such as cilostazol are currently used to treat IC. About Genovate Biotechnology Co., Ltd. Genovate Biotechnology Co., Ltd. is a Taiwan-based, fully integrated specialty pharmaceutical company focusing on the new drug development in new formulation, new active ingredient, new treatment modality in cardiovascular, autoimmune, neurodegenerative, and liver diseases. Genovate is equipped with PIC/S GMP manufacturing, marketing, and distribution capabilities. Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the timing of any regulatory process or ultimate approvals for PMR for the treatment of IC. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with the projected timeline of our NDA submission, whether FDA will agree with our interpretation of the data or the adequacy of data to support an NDA, the FDA's review of our NDA, market conditions, as well as risks and uncertainties inherent in Genovate's business. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. SOURCE Genovate Biotech

Drug ApprovalClinical ResultNDA

24 May 2024

·www.pharmaceutical-technology.com

Biocon and Handok link to commercialise Liraglutide in South Korea

Biocon will handle Liraglutide’s development, manufacturing and supply. Credit: Poetra.RH / Shutterstock.com. Indian biopharmaceutical company Biocon has entered an exclusive licence and supply agreement with Handok to commercialise synthetic Liraglutide in South Korea. A vertically integrated, complex drug, Liraglutide is administered using pre-filled injection pens. It is designed for chronic weight management alongside a reduced-calorie diet and increased physical activity. Biocon will handle Liraglutide’s development, manufacture and supply in South Korea. Handok will oversee the regulatory approvals and commercialisation of the product in the market. Handok’s diabetes care portfolio includes Amaryl, Tenelia and the real-time glucose monitoring device Barozen Fit. See Also: Alvotech and Dr Reddy’s partner to commercialise AVT03 (Cilostazol + rosuvastatin) by Korea United Pharm for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval Global contract research organisation IQVIA ‘s moving annual total for the fourth quarter of 2023 values the market opportunity for Liraglutide in South Korea at $47m. Biocon CEO and MD Siddharth Mittal stated: “We are pleased to enter into this strategic partnership with Handok, which will enable patients in South Korea dealing with weight management to gain access to our GLP-1 peptide drug product, synthetic Liraglutide. “This also aligns with our commitment to expand our portfolio of innovative, affordable medicines to address the unmet needs of patients around the world. We look forward to leveraging Handok’s strong capabilities to help patients in the region better manage their disease.” In December 2023, Biocon’s subsidiary Biocon Biologics completed the integration of Viatris’ biosimilars business across 31 European countries.

License out/inDrug Approval

13 Dec 2023

·synapse.patsnap.com

What are PDE3 inhibitors and how do you quickly get the latest development progress?

PDE3, or phosphodiesterase 3, is an enzyme found in the human body that plays a crucial role in regulating cellular signaling pathways. Specifically, PDE3 is responsible for breaking down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are important secondary messengers involved in various physiological processes. By inhibiting PDE3 activity, certain medications can increase the levels of cAMP and cGMP, leading to vasodilation, increased contractility of cardiac muscles, and platelet aggregation inhibition. This makes PDE3 an important target for pharmaceutical interventions aimed at treating cardiovascular diseases, such as heart failure and hypertension. The future of PDE3 inhibitors is promising. An agent that selectively inhibits sarcoplasmic reticulum-associated PDE3A-136 may help to preserve intracellular Ca2+ cycling and contractility in patients with dilated cardiomyopathy taking β-adrenergic receptor agonists. This may reduce arrhythmogenic effects attributable to increases in cytosolic cAMP content. Furthermore, given the promising results in preclinical models, numerous clinical trials have evaluated the therapeutic efficacy of PDE3 inhibitors against depression in humans. Therefore, the development of PDE3 inhibitors presents opportunities for innovation and competition in the pharmaceutical industry. The analysis of the target PDE3 reveals a competitive landscape with multiple companies actively involved in research and development. The highest stage of development is the "Approved" phase, indicating successful drug development in various indications. Small molecule drugs are progressing rapidly, with a significant number of approved and inactive drugs. China, Japan, the United States, and the European Union are leading in terms of drug development under the target PDE3. The future development of the target PDE3 is promising, with ongoing research and development efforts by various companies and countries/locations. How do they work?PDE3 inhibitors are a type of drug that target and inhibit the enzyme phosphodiesterase 3 (PDE3). Phosphodiesterases are a group of enzymes that play a crucial role in regulating cellular signaling pathways by breaking down cyclic nucleotides, specifically cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). In the context of biomedicine, PDE3 inhibitors are primarily used as cardiovascular drugs. They work by blocking the activity of PDE3, which leads to increased levels of cAMP and cGMP in cells. This, in turn, promotes vasodilation (relaxation of blood vessels), inhibits platelet aggregation (clumping of blood platelets), and reduces smooth muscle cell proliferation. These effects contribute to the treatment of conditions such as heart failure, angina (chest pain), and peripheral vascular disease. By inhibiting PDE3, these drugs enhance the effects of the cyclic nucleotides, which are important secondary messengers involved in various cellular processes. The increased levels of cAMP and cGMP can have beneficial effects on cardiac function, blood flow, and overall cardiovascular health. It's worth noting that PDE3 inhibitors may have side effects, including increased heart rate, arrhythmias, and potential interactions with other medications. Therefore, their use should be carefully monitored and prescribed by healthcare professionals. List of PDE3 InhibitorsThe currently marketed PDE3 inhibitors include: Cilostazol/ginkgo-bilobaLevosimendanEnoximoneAnagrelide HydrochlorideCilostazolOlprinone Hydrochloride HydrateIbudilastInamrinone LactateEnsifentrineCilostazol/DecanolFor more information, please click on the image below. What are PDE3 inhibitors used for?PDE3 inhibitors are under investigation for indications that include heart failure, angina (chest pain), and peripheral vascular disease. For more information, please click on the image below to log in and search. How to obtain the latest development progress of PDE3 inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of PDE3 inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

100 Deals associated with Cilostazol

External Link

KEGG	Wiki	ATC	Drug Bank
D01896	Cilostazol	B01AC23	DB01166

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Brain Infarction	Japan	Otsuka Pharmaceutical Co., Ltd.	15 Mar 2007
Arterial Occlusive Diseases	China	Zhejiang Otsuka Pharmaceutical Co. Ltd.	01 Jan 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Angina Pectoris, Variant	Discovery	South Korea	Korea Otsuka Pharmaceutical Co., Ltd.	01 Nov 2013
Brain Infarction	Discovery	China	Zhejiang Otsuka Pharmaceutical Co. Ltd.	01 May 2004
Brain Infarction	Discovery	China	Otsuka Beijing Research Institute	01 May 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01261234 (Randomized Controlled Trial of Cilostazol Addition for In-Stent Restenosis After Carotid Artery Stenting, Pubmed \| Stroke)	Not Applicable	Vascular restenosis	631	Cilostazol 50 mg	(gtlhvxzrdb) = wsiqyxwlea srvsconpau (vorjmpivrw ) View more	Positive	01 Dec 2024
				No Cilostazol	(gtlhvxzrdb) = nxcapzygfe srvsconpau (vorjmpivrw ) View more
NCT03451591 (LACI-2, CTgov)	Phase 2/3	Stroke, Lacunar	363	Isosorbide Mononitrate XL (ISMN) (Isosorbide Mononitrate XL (ISMN))	wnwktlrxzl(yokuubasuw) = hsjfqrhlmi shbclmlsvd (bxchrttmge, iuaamwbjjq - bcqaxixhcw) View more	-	12 Nov 2024
				Cilostazol (Cilostazol)	wnwktlrxzl(yokuubasuw) = vkllukqfws shbclmlsvd (bxchrttmge, frijkiwmtg - yexaizwbfq) View more
NCT02933788 (Pubmed \| Endocrinol Metab (Seoul))	Phase 4	Diabetes Mellitus	116	Aspirin 100 mg	iqttwvqjjs(qdeavoyqwg) = mjdvhoayym youjpgonsn (fekoouadws, 63.5%) View more	Negative	06 Apr 2022
				Cilostazol 200 mg	iqttwvqjjs(qdeavoyqwg) = gxcubhebuy youjpgonsn (fekoouadws, 54.1%) View more
NCT04069819 (Pubmed \| CNS Neurosci Ther)	Not Applicable	Depressive Disorder, Major	80	Cilostazol 50 mg	takirgbspk(tlfgbuzhoa) = rwfyffmjxp adoueozmkf (ijseijsvhk ) View more	Positive	01 Dec 2021
				Placebo	takirgbspk(tlfgbuzhoa) = vktyxzitsc adoueozmkf (ijseijsvhk ) View more
NCT01932203 (Pubmed \| Stroke)	Phase 4	Cerebral Small Vessel Diseases	256	Cilostazol	zvwzzjurup(vwwgaoiwgl): hazard ratio = 0.11 (95% CI, 0.02 - 0.89)	-	16 Nov 2021
				Aspirin
NCT02554721 (CiloMecT, CTgov)	Phase 1	-	77	Cilostazol+Acetylsalicylic Acid (Acetylsalicylic Acid - Cilostazol)	xztmclwpeb(rkwejwgdpq) = nsnlsrqake kkuccyfwqq (huabachhgm, wvzpndieef - tfqvyrgzhp) View more	-	13 Oct 2021
				Clopidogrel+Cilostazol (Clopidogrel - Cilostazol)	xztmclwpeb(rkwejwgdpq) = xxogzwqclc kkuccyfwqq (huabachhgm, rhprjrkrbf - swsuwzkqna) View more
DDW2021	Not Applicable	Stomach Ulcer	149	Low-dose aspirin	yzsqyduzqc(jdzfnbyqck) = smlqigxtdo egmyjsuruv (yjkrvpxnjk )	Negative	23 May 2021
				Clopidogrel	yzsqyduzqc(jdzfnbyqck) = rovhyjzkhw egmyjsuruv (yjkrvpxnjk )
ISN WCN2021	Not Applicable	Arteriovenous Fistula	194	Cilostazol	pacwqdudts(jsxyrnzajl) = exnitijewj dvftdbifsj (kdketzthjc ) View more	Positive	01 Apr 2021
				Cilostazol (Control)	pacwqdudts(jsxyrnzajl) = ejceehpode dvftdbifsj (kdketzthjc ) View more
NCT03248401 (Pubmed \| Diabetes Obes Metab)	Phase 4	Diabetes Mellitus, Type 2	50	Cilostazol 200 mg/day	qnxolfjpts(aoirplejjt) = pkvjsmxgqp hpjghdlmlu (ydxmjumhvl ) View more	Positive	22 Jul 2020
				Aspirin 100 mg/day	qnxolfjpts(aoirplejjt) = gpuxqtudfn hpjghdlmlu (ydxmjumhvl )
ISTH2020	Not Applicable	Diabetic foot ulcer	32	Cilostazol and Warfarin	hcmqwxvdfv(lafkjinqaq) = tmuxcrwdjq syiqprzwil (xgdplxgtdx, 0 - 28.11)	-	12 Jul 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis